1. Home
  2. HSPO vs VSTM Comparison

HSPO vs VSTM Comparison

Compare HSPO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • VSTM
  • Stock Information
  • Founded
  • HSPO 2014
  • VSTM 2010
  • Country
  • HSPO United States
  • VSTM United States
  • Employees
  • HSPO N/A
  • VSTM N/A
  • Industry
  • HSPO Blank Checks
  • VSTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • VSTM Health Care
  • Exchange
  • HSPO Nasdaq
  • VSTM Nasdaq
  • Market Cap
  • HSPO 87.7M
  • VSTM 132.0M
  • IPO Year
  • HSPO 2022
  • VSTM 2012
  • Fundamental
  • Price
  • HSPO $11.25
  • VSTM $3.88
  • Analyst Decision
  • HSPO
  • VSTM Strong Buy
  • Analyst Count
  • HSPO 0
  • VSTM 8
  • Target Price
  • HSPO N/A
  • VSTM $14.57
  • AVG Volume (30 Days)
  • HSPO 27.4K
  • VSTM 1.1M
  • Earning Date
  • HSPO 01-01-0001
  • VSTM 11-06-2024
  • Dividend Yield
  • HSPO N/A
  • VSTM N/A
  • EPS Growth
  • HSPO N/A
  • VSTM N/A
  • EPS
  • HSPO 0.33
  • VSTM N/A
  • Revenue
  • HSPO N/A
  • VSTM $10,000,000.00
  • Revenue This Year
  • HSPO N/A
  • VSTM N/A
  • Revenue Next Year
  • HSPO N/A
  • VSTM $125.69
  • P/E Ratio
  • HSPO $34.26
  • VSTM N/A
  • Revenue Growth
  • HSPO N/A
  • VSTM N/A
  • 52 Week Low
  • HSPO $10.60
  • VSTM $2.10
  • 52 Week High
  • HSPO $11.25
  • VSTM $14.22
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 69.42
  • VSTM 63.77
  • Support Level
  • HSPO $11.17
  • VSTM $3.11
  • Resistance Level
  • HSPO $11.25
  • VSTM $3.76
  • Average True Range (ATR)
  • HSPO 0.00
  • VSTM 0.33
  • MACD
  • HSPO 0.00
  • VSTM 0.04
  • Stochastic Oscillator
  • HSPO 100.00
  • VSTM 94.26

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: